Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized dose of Genotropin in short prepubertal children born small for gestational age (IDSGA)
2005-003146-33Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Nov 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in growth disorder (2 arms), sponsored by Pfizer. Primary endpoint: Change in DIFF SDS from baseline to 36 months. Started Nov 2006; status: terminated.
02
Drugs
somatropin
03
Conditions
growth disorder
Beyond the preview
Go deeper on 2005-003146-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003146-33.